Svetlana Mojsov: Pioneering GLP-1 Research and Its Global Impact

In a significant advancement in metabolic disease care, Dr. Svetlana Mojsov, a prominent biochemist and research associate professor at Rockefeller University, has been honored with the Frontiers of Knowledge Award in Biology and Biomedicine by Spain's BBVA Foundation. This recognition is a testament to her pivotal role in the discovery of the hormone glucagon-like peptide-1 (GLP-1), which has transformed the management of type 2 diabetes (T2D) and obesity, ultimately benefiting millions of patients worldwide.

Dr. Mojsov's groundbreaking research, conducted alongside esteemed colleagues Dr. Daniel Drucker, Dr. Joel Habener, and Dr. Jens Holst, elucidated the biological function of GLP-1, a critical regulator of glucose metabolism and appetite. Their collective findings, which have paved the way for a new class of therapies, were first published in the early 1980s and have since culminated in the development of effective GLP-1 receptor agonists that are widely prescribed today.

During a recent interview with *El Médico Interactivo* following the award ceremony in Bilbao, Spain, Dr. Mojsov expressed her gratitude for contributing to advancements that significantly improve health outcomes. "These drugs not only enhance glycemic control but also promote weight loss and reduce cardiovascular risk, which are essential for patients struggling with T2D and obesity," she stated.

Historically, GLP-1-based therapies represent a paradigm shift in diabetes treatment. Dr. Mojsov noted that prior to these therapies, many existing treatments often resulted in weight gain, thus exacerbating patient conditions. The introduction of GLP-1 receptor agonists has allowed for weight reductions of up to 20%, a crucial factor considering that excess weight can worsen T2D prognosis.

Reflecting on her earlier work, Dr. Mojsov shared insights into her journey as a scientist. Her interest in peptide-based therapies for glucose metabolism dates back to her graduate studies in the mid-1970s at Rockefeller University, where she worked under the guidance of the Nobel Laureate Dr. Bruce Merrifield. This foundational research led her to identify the biologically active form of GLP-1 in the early 1980s at Massachusetts General Hospital, a discovery that would eventually lead to the development of life-changing therapies.

One of the noteworthy aspects of Dr. Mojsov's research journey has been the collaboration across various disciplines. She emphasized that while her initial work on GLP-1 was conducted independently, collaboration with biologists and clinical researchers played a crucial role in advancing the understanding and application of her findings.

Despite the transformative potential of GLP-1 therapies, Dr. Mojsov acknowledges that cost remains a significant barrier to access, particularly in low- and middle-income countries. "These therapies must become more affordable to truly benefit public health on a global scale," she asserted. She expressed optimism that continued innovation in drug development could lead to reduced costs and improved accessibility for patients in need.

Looking ahead, Dr. Mojsov is hopeful about the future of GLP-1 therapies, especially as research continues to unveil their broader therapeutic applications. Current studies suggest potential benefits for cardiovascular health and kidney function, with ongoing investigations into their effects on neurodegenerative diseases and addiction.

As Dr. Mojsov reflects on her contributions to science, she acknowledges the importance of perseverance and discipline for aspiring researchers. She encourages young scientists, especially women, to advocate for their work and push for recognition of their contributions. "Every breakthrough starts with knowledge, and we must protect and support scientific research to ensure continued progress in health and medicine," she concluded.

Dr. Svetlana Mojsov’s journey from her early days in Yugoslavia to becoming a leader in the field of biochemistry exemplifies the impact of dedication and collaboration in advancing medical science. As GLP-1 therapies continue to evolve, their potential to reshape the landscape of metabolic disease management remains significant, offering hope and improved quality of life for millions of patients worldwide.